Despite demonstration of decreased cardiovascular risk with lowered postprandial glucose levels and the availability of fast-acting insulins to treat postprandial glucose excursions (PPGE), debate remains about the necessity of treating PPGE. It is critical that clinicians who manage patients with diabetes keep up to date with the latest emerging evidence for newer, ultra-fast-acting prandial insulins, as this is an evolving category.
Whereas prandial insulin use primarily pertains to type 1 diabetes, a number of people with type 2 diabetes also benefit from prandial insulin. Endocrinologists and diabetes specialists need to understand how to tailor diabetes care according to individual patient backgrounds and characteristics, especially with respect to prandial insulin. They also require an understanding of the most recently updated guidelines about the appropriate use of prandial insulin therapy, and how patient factors influence selection of appropriate insulin regimens.
This educational activity will address postprandial hyperglycemia and its treatment.
Upon proper completion of this activity, participants should be better able to:
• Discuss the implications of postprandial hyperglycemia for patients with diabetes.
• Describe how ultra-fast-acting insulins are used to mimic physiologic insulin for patients with diabetes.
• Outline appropriate use of ultra-fast-acting insulins for patients with diabetes.
This activity has been designed to address the educational needs of endocrinologists. It may also benefit
- Diabetes specialists
- Primary care physicians
- Certified diabetes educators
- Physicians Assistants (PAs)
- Nurse practitioners (NPs)
- Managed care clinicians
- Other clinicians who care for patients with diabetes.